Aprea CEO @DrOrenGilad, Ph.D. shares his view on how the next wave of ovarian cancer trials is being organized around specific genetic changes, and how that approach shapes our WEE1 and ATR programs. Read his post: bit.ly/4sxoAu1 $APRE
WEE1 inhibition represents a novel approach to precision oncology, targeting vulnerabilities in cancer cells’ DDR rather than a single oncogenic driver.
In our recent panel, Dr. Alex Spira discussed what makes this emerging therapeutic class exciting. Watch here: bit.ly/4yVw7Fr $APRE
Why is WEE1 such a compelling target in precision oncology?
Aprea CMO Eugene Kennedy, MD, discusses the clinical evidence supporting WEE1 inhibition and the challenge of expanding the therapeutic window to help patients benefit from treatment. Watch here: bit.ly/4yVw7Fr $APRE
Hear experts Eugene Kennedy, $APRE CMO, Dr. Alex Spira, of Virginia Cancer Specialists Research Institute and NEXT Oncology, and Kevin DeGeeter of @LadenburgLTS discuss the science, clinical and market potential of WEE1 inhibition, moderated by @SolomonsWisdom: bit.ly/4yVw7Fr
The replay of our “State of WEE1 Inhibition in Precision Oncology” is now available.
Moderated by @SolomonsWisdom, the panel explored WEE1 inhibition’s emerging role in precision oncology with experts across clinical and equity research. bit.ly/4yVw7Fr $APRE
Today at 11 AM ET, join $APRE Chief Medical Advisor, Dr. Eugene Kennedy, and leading experts for a pre-#ESMO2026 virtual panel exploring the evolving WEE1 inhibitor landscape.
Register for “The State of WEE1 Inhibition in Precision Oncology”: bit.ly/4yVw7Fr
Tomorrow: Join Aprea at 11:00 AM ET for “The State of WEE1 Inhibition in Precision Oncology,” a pre-ESMO virtual panel featuring experts in oncology and biotechnology.
Register here: bit.ly/4yVw7Fr #ESMO2026 $APRE
Join Aprea on Tuesday, Oct. 20 at 11 AM ET for a pre-#ESMO2026 virtual panel covering WEE1's biology, the selectivity challenge that has shaped the class, and what to watch in the months ahead, across scientific, clinical, and market perspectives. Register: bit.ly/3Wwbf9d $APRE
Oren Gilad, Ph.D., CEO of Aprea, will participate in a fireside chat tomorrow, Tuesday, October 14 at 9:00 a.m. ET, at the 2026 @MaximGrp Growth Summit in New York City. For details: bit.ly/4rPCGGO $APRE
Aprea will participate in a panel discussion at the #PABC Regional Biotechnology Conference 2026 on October 15th, from 9:00 a.m. to 12:00 p.m. ET at the Pennsylvania Biotechnology Center in Doylestown, PA. For details: bit.ly/4rPCGGO $APRE
Aprea CEO Oren Gilad joined NanoCap Podcast to discuss targeted cancer therapies, the science behind synthetic lethality, and Aprea’s latest clinical progress. Hear how innovative approaches could help advance new treatment options for patients: bit.ly/478AikZ $APRE
Oren Gilad Ph.D., President and CEO, will participate in the 2026 @MaximGrp Growth Summit, to take place October 12-14 in NYC and the #PABC Regional Biotechnology Conference, to take place October 15 in Doylestown, PA. For details, visit: bit.ly/4rPCGGO $APRE
“We look forward to presenting an update from our ongoing Phase 1 ACESOT-1051 trial at the EORTC-NCI-AACR Symposium and sharing these data with the international oncology community,” said Oren Gilad, Ph.D., President and CEO of Aprea. Read more: bit.ly/3TK8UXl $APRE
An abstract featuring updated interim results from Aprea's ongoing Ph.1 ACESOT-1051 study of WEE1 inhibitor APR-1051 in advanced solid tumors has been accepted for oral presentation at the 38th #ENAsymp26, on Nov. 18-20, in Spain. bit.ly/3TK8UXl $APRE
“The first thing I could say to a newly diagnosed cancer patient is that there’s hope.”
$APRE CEO Oren Gilad, Ph.D. joined @chrisleidli on #RxforBiotech to discuss precision oncology, synthetic lethality, and the science behind our investigational therapies. bit.ly/4ix6Dc7
A webcast of Aprea President and CEO Oren Gilad, Ph.D.'s presentation at the @HCWCO 28th Annual Global Investment Conference is now available. Tune-in here: bit.ly/4yBbqhc $APRE
In a recent interview with GEN, Oren Gilad, Ph.D., Aprea’s President and CEO, said the early clinical activity data from our WEE1 inhibitor, APR-1051, marks an important moment for the program.
As Gilad stated in the interview, "We saw tumor shrinkage and very tolerable side effects."
Building on this momentum, the company is accelerating enrollment and expanding the development of APR-1051 into additional biomarker-defined tumor populations and combination settings.
Read more about APR-1051 and what’s next in this new feature from @GENbio: bit.ly/4hfQM0n $APRE
“You have to build this thing one brick at a time.”
In a new interview with @ClinicalLeader1, Aprea Chief Medical Advisor, Eugene Kennedy, MD, shares how Aprea is taking an intentional approach to the clinical development of APR-1051, from identifying the patients most likely to benefit to planning for future combination strategies. Read the full article: bit.ly/3VovWmU $APRE
Oren Gilad, Ph.D., President and CEO of Aprea Therapeutics, will present at the H.C. Wainwright 28th Annual Global Investment Conference, to be held September 14-16, 2026. For details, visit: bit.ly/3UKOCgx $APRE